Terms: = Breast cancer AND uPA AND Clinical Outcome
22 results:
1. cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis.
Eiro N; González L; Martínez-Ordoñez A; Fernandez-Garcia B; González LO; Cid S; Dominguez F; Perez-Fernandez R; Vizoso FJ
Cell Oncol (Dordr); 2018 Aug; 41(4):369-378. PubMed ID: 29497991
[TBL] [Abstract] [Full Text] [Related]
2. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker upa/PAI-1.
Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic impact of the inclusion of upa/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.
Viala M; Alexandre M; Thezenas S; Lamy PJ; Maran-Gonzalez A; Gutowski M; Colombo PE; Romieu G; Jacot W; Guiu S
Breast Cancer Res Treat; 2017 Oct; 165(3):611-621. PubMed ID: 28685212
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic Potentials of BDNF/TrkB in breast cancer; Current Status and Perspectives.
Tajbakhsh A; Mokhtari-Zaer A; Rezaee M; Afzaljavan F; Rivandi M; Hassanian SM; Ferns GA; Pasdar A; Avan A
J Cell Biochem; 2017 Sep; 118(9):2502-2515. PubMed ID: 28230291
[TBL] [Abstract] [Full Text] [Related]
5. Impact of guideline-based use of upa/PAI-1 on patient outcome in intermediate-risk early breast cancer.
Kolben T; Augustin D; Armbrust R; Kolben TM; Degenhardt T; Burgmann M; Goess C; Ditsch N; Kates R; Harbeck N; Wuerstlein R
Breast Cancer Res Treat; 2016 Jan; 155(1):109-15. PubMed ID: 26643086
[TBL] [Abstract] [Full Text] [Related]
6. Expression of urokinase-type plasminogen activator (upa), its receptor (upaR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Andres SA; Edwards AB; Wittliff JL
J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
[TBL] [Abstract] [Full Text] [Related]
7. upa and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.
Annecke K; Schmitt M; Euler U; Zerm M; Paepke D; Paepke S; von Minckwitz G; Thomssen C; Harbeck N
Adv Clin Chem; 2008; 45():31-45. PubMed ID: 18429492
[TBL] [Abstract] [Full Text] [Related]
8. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
[TBL] [Abstract] [Full Text] [Related]
9. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
[TBL] [Abstract] [Full Text] [Related]
10. upaR and HER-2 gene status in individual breast cancer cells from blood and tissues.
Meng S; Tripathy D; Shete S; Ashfaq R; Saboorian H; Haley B; Frenkel E; Euhus D; Leitch M; Osborne C; Clifford E; Perkins S; Beitsch P; Khan A; Morrison L; Herlyn D; Terstappen LW; Lane N; Wang J; Uhr J
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17361-5. PubMed ID: 17079488
[TBL] [Abstract] [Full Text] [Related]
11. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract] [Full Text] [Related]
12. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
Ryan BM; Konecny GE; Kahlert S; Wang HJ; Untch M; Meng G; Pegram MD; Podratz KC; Crown J; Slamon DJ; Duffy MJ
Ann Oncol; 2006 Apr; 17(4):597-604. PubMed ID: 16403812
[TBL] [Abstract] [Full Text] [Related]
13. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.
Zhou Y; Eppenberger-Castori S; Marx C; Yau C; Scott GK; Eppenberger U; Benz CC
Int J Biochem Cell Biol; 2005 May; 37(5):1130-44. PubMed ID: 15743683
[TBL] [Abstract] [Full Text] [Related]
14. New data on chemotherapy in the adjuvant setting.
Piccart MJ; Sotiriou C; Cardoso F
Breast; 2003 Dec; 12(6):373-8. PubMed ID: 14659108
[TBL] [Abstract] [Full Text] [Related]
15. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract] [Full Text] [Related]
16. clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
Harbeck N; Krüger A; Sinz S; Kates RE; Thomssen C; Schmitt M; Jänicke F
Onkologie; 2001 Jun; 24(3):238-44. PubMed ID: 11455216
[TBL] [Abstract] [Full Text] [Related]
17. Functional evaluation of plasmin formation in primary breast cancer.
Chappuis PO; Dieterich B; Sciretta V; Lohse C; Bonnefoi H; Remadi S; Sappino AP
J Clin Oncol; 2001 May; 19(10):2731-8. PubMed ID: 11352966
[TBL] [Abstract] [Full Text] [Related]
18. breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
Meijer-van Gelder ME; Look MP; Bolt-de Vries J; Peters HA; Klijn JG; Foekens JA
J Clin Oncol; 1999 May; 17(5):1449-57. PubMed ID: 10334530
[TBL] [Abstract] [Full Text] [Related]
19. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression.
Graham CH; Forsdike J; Fitzgerald CJ; Macdonald-Goodfellow S
Int J Cancer; 1999 Feb; 80(4):617-23. PubMed ID: 9935166
[TBL] [Abstract] [Full Text] [Related]
20. Are patients who present late with cancer registered with low referring practices?
Hippisley-Cox J; Hardy C; Pringle M; Fielding K; Carlisle R; Chilvers C; Avery A
Br J Gen Pract; 1997 Nov; 47(424):731-2. PubMed ID: 9519522
[TBL] [Abstract] [Full Text] [Related]
[Next]
